Equity Overview
Price & Market Data
Price: $1.11
Daily Change: $0.00 / 0.00%
Daily Range: $0.963 - $1.14
Market Cap: $46,482,460
Daily Volume: 664,393
Performance Metrics
1 Week: 4.72%
1 Month: -9.02%
3 Months: -26.49%
6 Months: -15.91%
1 Year: 17.09%
YTD: -26.49%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.